Challenges of Creating New Tumor-Infiltrating Lymphocyte for Combating Breast Cancer
Authors: Paul A. Beavis, Emily B. Derrick, Sherene Loi
Journal: Journal of Clinical Oncology (2022)

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes. February 01, 2022 ARTICLE CITATION DOI: 10.1200/JCO.22.00284 Journal of Clinical Oncology - published online before print April 19, 2022 PMID: 35439032 Challenges of Creating New Tumor-Infiltrating Lymphocyte for Combating Breast Cancer Paul A. Beavis, PhD1,2xPaul A. BeavisSearch for articles by this author; Emily B. Derrick , MSc1xEmily B. DerrickSearch for articles by this author; and Sherene Loi , PhD, MD1,2xSherene LoiSearch for articles by this author Show More 1Peter MacCallum Cancer Centre, Melbourne, Australia2Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia https://doi.org/10.1200/JCO.22.00284 First Page Full Text PDF Figures and Tables © 2022 by American Society of Clinical OncologySUPPORTSupported by the National Breast Cancer Foundation of Australia (S.L.).AUTHOR CONTRIBUTIONSConception and design: All authorsAdministrative support: Sherene LoiCollection and assembly of data: Sherene LoiData analysis and interpretation: Paul A. Beavis, Sherene LoiManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTChallenges of Creating New Tumor-Infiltrating Lymphocyte for Combating Breast CancerThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Paul A. BeavisResearch Funding: AstraZeneca/MedImmune (Inst), Bristol Myers Squibb (Inst), Gilead Sciences (Inst)Patents, Royalties, Other Intellectual Property: 2 × patents relating to CAR T-cell technology. No funds payable at the time reportedSherene LoiConsulting or Advisory Role: Roche/Genentech (Inst), Aduro Biotech (Inst), Novartis (Inst), G1 Therapeutics (Inst), PUMA Biotechnology (Inst), GlaxoSmithKline (Inst), AstraZeneca (Inst), Seattle Genetics (Inst), BMS (Inst), Silverback Therapeutics (Inst), Pfizer (Inst), Gilead Sciences (Inst), Gilead Sciences (Inst), Daiichi Sankyo/Lilly (Inst), Tallac Therapeutics (Inst)Research Funding: Roche/Genentech (Inst), Novartis (Inst), Merck (Inst), Puma Biotechnology (Inst), Bristol Myers Squibb (Inst), Seattle Genetics (Inst), AstraZeneca (Inst), Nektar (Inst), Lilly (Inst)Other Relationship: Roche Medical writing supportNo other potential conflicts of interest were reported. Companion Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes